2015
Adjuvant inhibition of iAPC function in the tumor microenvironment promotes therapeutic immunity in the setting of vaccination-induced T cell anti-tumor response
Antonios J, Soto H, Orpilla J, Shin N, Everson R, Liau L, Prins R. Adjuvant inhibition of iAPC function in the tumor microenvironment promotes therapeutic immunity in the setting of vaccination-induced T cell anti-tumor response. Journal For ImmunoTherapy Of Cancer 2015, 3: p393. PMCID: PMC4652564, DOI: 10.1186/2051-1426-3-s2-p393.Peer-Reviewed Original Research
2014
IT-01PD1/PDL1 INTERACTIONS MEDIATE SUPPRESSION OF ANTI-TUMOR IMMUNE ACTIVITY IN GLIOMA
Antonios J, Soto H, Harris R, Nathanson D, Sadeghi S, Ellingson B, Liau L, Prins R. IT-01PD1/PDL1 INTERACTIONS MEDIATE SUPPRESSION OF ANTI-TUMOR IMMUNE ACTIVITY IN GLIOMA. Neuro-Oncology 2014, 16: v110-v110. PMCID: PMC4218227, DOI: 10.1093/neuonc/nou258.1.Peer-Reviewed Original ResearchProgrammed death-1Tumor-infiltrating lymphocytesPost-implant dayCombination groupPD-1Tumor microenvironmentLymph nodesTreatment groupsEffective anti-tumor immune responseFACS analysisAnti-tumor immune activityAnti-tumor immune responseIncreased tumor-infiltrating lymphocytesAnti-PD1 mAbNegative costimulatory moleculesPD-1 mAbDendritic cell vaccinesAnti-tumor responsesImmunocompetent C57BL/6 miceTumor-bearing hemisphereDecreased tumor volumeGL261 glioma cellsCombined treatment groupAntitumor responseDeath-1